Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

39.63USD
23 May 2018
Change (% chg)

$0.42 (+1.07%)
Prev Close
$39.21
Open
$38.97
Day's High
$39.71
Day's Low
$38.84
Volume
3,809,104
Avg. Vol
4,806,444
52-wk High
$47.82
52-wk Low
$29.39

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 30.95 32.75
EPS (TTM): 1.23 -- --
ROI: 2.39 14.84 14.38
ROE: 5.71 16.34 16.07

DoJ investigates Mylan on trade compliance for certain products

Pharmaceuticals company Mylan NV said on Thursday that one of its subsidiary received a civil investigative demand from the U.S. Department of Justice regarding its compliance with the Trades Agreement Act (TAA) for certain products, according to a filing with the U.S. Securities and Exchange Commission.

May 10 2018

U.S. DoJ investigates Mylan on trade compliance for certain products

May 10 Pharmaceuticals company Mylan NV said on Thursday that one of its subsidiary received a civil investigative demand from the U.S. Department of Justice regarding its compliance with the Trades Agreement Act (TAA) for certain products, according to a filing with the U.S. Securities and Exchange Commission. The company also said certain employees of Mylan S.p.A. were served with search warrants issued by the public prosecutor's office in Milan, Italy, seeking information concerni

May 10 2018

BRIEF-Mylan Says Non-Contingent Payments For 4 Agreements Total About $265 Mln

* MYLAN NV - NON-CONTINGENT PAYMENTS FOR 4 AGREEMENTS, 3 OF WHICH WERE ENTERED INTO AFTER MARCH 31, 2018, TOTAL ABOUT $265.0 MILLION - SEC FILING

May 10 2018

In Europe, Mylan's rivals try to plug EpiPen shortages

LONDON European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's market-leading EpiPen injection.

May 10 2018

UPDATE 1-In Europe, Mylan's rivals try to plug EpiPen shortages

LONDON, May 10 European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's market-leading EpiPen injection.

May 10 2018

In Europe, Mylan's rivals try to plug EpiPen shortages

LONDON, May 10 European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's market-leading EpiPen injection.

May 10 2018

FDA says Mylan's EpiPen is in shortage in U.S.

U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video

May 09 2018

UPDATE 3-FDA says Mylan's EpiPen is in shortage in U.S.

May 9 U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

May 09 2018

Mylan says U.S. customers may have trouble getting EpiPens

NEW YORK Mylan NV said on Tuesday that U.S. consumers may have difficulty getting EpiPen prescriptions filled after manufacturing problems constrained supply, but the drugmaker did not say there was a shortage of its emergency allergy treatment. | Video

May 09 2018

FDA says manufacturing delays are constraining EpiPen supply

NEW YORK, May 9 The U.S. Food and Drug Administration added Mylan NV's EpiPen to its list of drugs in shortage on Wednesday, saying that manufacturing delays were creating intermittent supply constraints of the emergency allergy treatment.

May 09 2018

Earnings vs. Estimates